Luminex Stock Price, News & Analysis (NASDAQ:LMNX)

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex declared a quarterly dividend on Wednesday, July 31st. Investors of record on Thursday, September 26th will be given a dividend of $0.09 per share on Thursday, October 17th. This represents a $0.36 annualized dividend and a yield of 1.78%. The ex-dividend date is Wednesday, September 25th. This is a boost from Luminex's previous quarterly dividend of $0.06. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Wednesday, July, 31st. The medical instruments supplier reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.09. The medical instruments supplier earned $83.06 million during the quarter, compared to analyst estimates of $81.61 million. Luminex had a negative net margin of 0.80% and a negative return on equity of 0.78%. The firm's revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.15 earnings per share. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Luminex.

Luminex issued an update on its third quarter 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $80-83 million, compared to the consensus revenue estimate of $83.01 million.

3 brokerages have issued 1 year target prices for Luminex's shares. Their forecasts range from $21.00 to $33.00. On average, they expect Luminex's stock price to reach $27.00 in the next year. This suggests a possible upside of 33.5% from the stock's current price. View Analyst Price Targets for Luminex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Media headlines about LMNX stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Luminex earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the stock's share price in the near future. View News Stories for Luminex.

Luminex saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 1,000,000 shares, a decline of 30.6% from the August 30th total of 1,440,000 shares. Based on an average daily trading volume, of 189,400 shares, the days-to-cover ratio is currently 5.3 days. Currently, 2.4% of the company's stock are short sold. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Inspire Medical Systems (INSP), AtriCure (ATRC), Orthofix Medical (OFIX), Silk Road Medical (SILK) and Cryolife (CRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Mondi (MNDI), Alphabet (GOOG), Intel (INTC), Micron Technology (MU), Nektar Therapeutics (NKTR), Rocket Pharmaceuticals (RCKT), Verizon Communications (VZ), Cree (CREE) and Ligand Pharmaceuticals (LGND).

Luminex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $20.23.

Luminex has a market capitalization of $911.36 million and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]